- Home
- MDGL
as 07-08-2024 4:00pm EST
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | WEST CONSHOHOCKEN |
| Market Cap: | 5.9B | IPO Year: | N/A |
| Target Price: | $348.17 | AVG Volume (30 days): | 433.6K |
| Analyst Decision: | Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -23.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $119.76 - $299.98 | Next Earning Date: | 08-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 342.62% |
Stock Insider Trading Activity of Madrigal Pharmaceuticals Inc. (MDGL)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Waltermire Robert E. | MDGL | Senior VP, Chief Pharma Dev. | Jun 14 '24 | Sell | $280.00 | 1,900 | $532,000.00 | 5,500 | SEC Form 4 |
| Waltermire Robert E. | MDGL | Senior VP, Chief Pharma Dev. | Jun 12 '24 | Sell | $285.00 | 2,000 | $570,000.00 | 5,500 | SEC Form 4 |
| Waltermire Robert E. | MDGL | Senior VP, Chief Pharma Dev. | May 21 '24 | Sell | $231.34 | 1,036 | $239,668.24 | 5,500 | SEC Form 4 |
| CRAVES FRED B | MDGL | Director | May 14 '24 | Sell | $219.90 | 100 | $21,990.00 | 413,362 | SEC Form 4 |
| CRAVES FRED B | MDGL | Director | May 14 '24 | Sell | $218.99 | 1,000 | $218,994.50 | 413,462 | SEC Form 4 |
| CRAVES FRED B | MDGL | Director | May 14 '24 | Sell | $217.86 | 1,100 | $239,640.83 | 414,462 | SEC Form 4 |
| CRAVES FRED B | MDGL | Director | May 14 '24 | Sell | $216.98 | 721 | $156,445.32 | 415,562 | SEC Form 4 |
| CRAVES FRED B | MDGL | Director | May 14 '24 | Sell | $216.08 | 375 | $81,031.35 | 416,283 | SEC Form 4 |
| CRAVES FRED B | MDGL | Director | May 14 '24 | Sell | $214.68 | 1,804 | $387,285.43 | 416,658 | SEC Form 4 |
| CRAVES FRED B | MDGL | Director | May 14 '24 | Sell | $213.85 | 2,190 | $468,342.01 | 418,462 | SEC Form 4 |
| CRAVES FRED B | MDGL | Director | May 14 '24 | Sell | $212.85 | 1,363 | $290,116.32 | 420,652 | SEC Form 4 |
| CRAVES FRED B | MDGL | Director | May 14 '24 | Sell | $211.84 | 5,009 | $1,061,126.60 | 422,015 | SEC Form 4 |
| CRAVES FRED B | MDGL | Director | May 14 '24 | Sell | $210.99 | 8,827 | $1,862,431.68 | 427,024 | SEC Form 4 |
| Taub Rebecca | MDGL | Pres., R&D, and CMO | Apr 8 '24 | Sell | $243.25 | 224 | $54,486.88 | 461,451 | SEC Form 4 |
| Taub Rebecca | MDGL | Pres., R&D, and CMO | Apr 8 '24 | Sell | $244.79 | 945 | $231,324.75 | 460,506 | SEC Form 4 |
| Taub Rebecca | MDGL | Pres., R&D, and CMO | Apr 8 '24 | Sell | $245.69 | 300 | $73,706.01 | 460,206 | SEC Form 4 |
| Taub Rebecca | MDGL | Pres., R&D, and CMO | Apr 8 '24 | Sell | $246.98 | 600 | $148,186.38 | 459,606 | SEC Form 4 |
| Taub Rebecca | MDGL | Pres., R&D, and CMO | Apr 8 '24 | Sell | $247.76 | 407 | $100,837.59 | 459,199 | SEC Form 4 |
| Taub Rebecca | MDGL | Pres., R&D, and CMO | Apr 8 '24 | Sell | $248.58 | 200 | $49,716.00 | 458,999 | SEC Form 4 |
| FRIEDMAN PAUL A | MDGL | Director | Apr 8 '24 | Sell | $242.95 | 1,441 | $350,094.26 | 210,564 | SEC Form 4 |
| FRIEDMAN PAUL A | MDGL | Director | Apr 8 '24 | Sell | $244.12 | 3,730 | $910,566.48 | 206,834 | SEC Form 4 |
| FRIEDMAN PAUL A | MDGL | Director | Apr 8 '24 | Sell | $244.86 | 5,663 | $1,386,646.14 | 201,171 | SEC Form 4 |
| FRIEDMAN PAUL A | MDGL | Director | Apr 8 '24 | Sell | $245.71 | 2,078 | $510,590.78 | 199,093 | SEC Form 4 |
| FRIEDMAN PAUL A | MDGL | Director | Apr 8 '24 | Sell | $246.96 | 5,028 | $1,241,709.85 | 194,065 | SEC Form 4 |
| FRIEDMAN PAUL A | MDGL | Director | Apr 8 '24 | Sell | $247.76 | 3,464 | $858,240.99 | 190,601 | SEC Form 4 |
Latest Madrigal Pharmaceuticals Inc. News
MDGL Breaking Stock News: Dive into MDGL Ticker-Specific Updates for Smart Investing
Simply Wall St.
5 days ago
Unveiling Three US Growth Companies With High Insider Ownership
Motley Fool
8 days ago
Is Madrigal Pharmaceuticals a Millionaire Maker?
MT Newswires
10 days ago
Cantor Fitzgerald Starts Madrigal Pharmaceuticals With Neutral Rating
Motley Fool
10 days ago
Is Madrigal Pharmaceuticals Stock a Buy?
Motley Fool
22 days ago
Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.
Motley Fool
23 days ago
Where Will Madrigal Pharmaceuticals Be in 3 Years?
Investor's Business Daily
a month ago
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
Motley Fool
a month ago
Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals
Share on Social Networks:
Disclaimer
The information presented on this page, "MDGL Madrigal Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.